Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Nov. 7 — Can consumers receive adequate information about the risks associated with prescription drugs promoted on social media by clicking on a separate link? The FDA plans to find out.
The Food and Drug Administration will study whether linking to prescription drug risk information can effectively convey the risks associated with prescription drugs marketed on character-space-limited outlets like Twitter and microblogs, it said in a Nov. 7 Federal Register notice (81 Fed. Reg. 78,163).
The issue is important to the drug Industry because it wants to use the one-click approach to presenting drug risk information without facing government enforcement action.
“It’s time for the FDA to enable robust communication in searches and on Twitter,” John Kamp, executive director of the Coalition for Healthcare Communication in New York and consulting counsel to Wiley Rein LLP told Bloomberg BNA Nov. 7. “This study could go far to advance that goal.”
Nonetheless, Kamp is concerned that the FDA’s stated hypothesis for the studies “suggests that the status quo is needed to ensure that the risk information is fully understood.”
“Given the plethora of bad information by others on the Internet, sponsor [drug company] communication should be encouraged, not discouraged,” Kamp said.
Composed of media, health-care and other organizations, the Coalition for Healthcare Communication promotes the free exchange of scientific and medical information.
Kamp also said the FDA’s study proposal appears to be the agency’s attempt to make good on a promise Janet Woodcock, director of the FDA‘s Center for Drug Evaluation and Research, made to Rep. Billy Long (R-Mo.) in connection with H.R. 2479. Long introduced that bill in 2015 to update FDA’s regulation of online drug promotion, Kamp said.
Long’s bill would let pharmaceutical companies provide consumers with drug risk information by clicking on a separate link. The bill was included in early drafts of the 21st Century Cures legislation, legislation aimed at spurring development of new medical treatments and prevention therapies. But Long’s bill was subsequently dropped from the Cures bill and is now at the House Energy and Commerce Committee’s Subcommittee on Health.
Bloomberg BNA reached out to consumer groups including Public Citizen for comment on the FDA’s proposed studies Nov. 7 but no one was available to comment.
Comments on the studies are due Jan. 6, 2017.
To contact the reporter on this story: Dana A. Elfin in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
The Federal Register notice is available at http://src.bna.com/jT8.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)